Page 1

Allogene THERAPEUTICS Allogene Therapeutics Reports Second Quarter 2021 Financial Results August 4 , 2021 CD19 Program Highlights • Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO - 501 was Associated with Overall Response , Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed / Refractory Non - Hodgkin Lymphoma • Next CD19 Program Clinical Update Planned for Q4 2021 • ALLO - 501A Pivotal Trial on Track for Initiation in Late 2021 BCMA Program Highlights • Updated Phase 1 UNIVERSAL Data on ALLO - 715 Planned for Q4 2021 • Began Dosing Patients in Phase 1 IGNITE Trial of ALLO - 605 , the First TurboCARTM T Cell Therapy , for Relapsed / Refractory Multiple Myeloma • ALLO - 605 Granted Fast Track Designation by the FDA Solid Tumor Program Highlights • Phase 1 TRAVERSE Trial Ongoing for ALLO - 316 ( anti - CD70 ) in Advanced or Metastatic Renal Cell Carcinoma . Initial Clinical Readout Expected in 2022 Corporate Highlights • Appointed Liz Barrett and Vicki Sato , Ph.D. , Executives with Significant Strategic and Commercial Expertise , to the Board of Directors • State - of - the - Art cGMP Manufacturing Facility in Newark , California to Support Industry's First Allogeneic Pivotal Trial and Future Commercial Launch • Ended Second Quarter with $ 913 Million in Cash , Cash Equivalents and Investments Quarterly Conference Call and Webcast Scheduled for 2:00 PM PT / 5 : 00 PM ET SOUTH SAN FRANCISCO , Calif . , Aug. 04 , 2021 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics , Inc. ( Nasdaq : ALLO ) , a clinical - stage biotechnology company pioneering the development of allogeneic CART ( AlloCAR TTM ) therapies for cancer , today provided a corporate update and reported second quarter 2021 financial results for the quarter ended June 30 , 2021 . " We have made exceptional progress across our broad pipeline of AlloCAR T candidates , bringing our goal of revolutionizing cell therapy for patients with blood cancers and solid tumors closer to reality , " said David Chang , M.D. , Ph.D. , President , Chief Executive Officer and Co - Founder of Allogene . " Our foundational and ongoing work has the potential to drive us toward an industry first - our planned pivotal trial for ALLO - 501A in relapsed / refractory non - Hodgkin lymphoma which we expect to initiate at the end of this year . This month , we are also marking an exciting milestone with the planned inauguration of our state - of - the - art manufacturing facility , Cell Forge 1. This facility is intended to allow us to control manufacturing of ALLO - 501A and future therapies and prepare us for potential commercialization . " Pipeline Highlights Anti - CD19 Program : ALPHA and ALPHA2 Trials • Updated data from the ongoing Phase 1 ALPHA ( ALLO - 501 ) and ALPHA2 ( ALLO - 501A ) trials in relapsed / refractory non - Hodgkin lymphoma ( NHL ) presented at the Company's CD19 Forum in May and Annual Meeting of the American Society of Clinical Oncology ( ASCO ) in June . • Data from the ALPHA trial supports the ability of a single administration of ALLO - 501 to generate deep and durable responses at a rate that is similar to approved autologous CAR T therapies . In the trial , 98 % of patients received ALLO - 501 with an average time from enrollment to the start of therapy of five days . • Durable complete responses ( CR ) were observed with the longest ongoing CR at 15 months in both large B cell lymphoma ( LBCL ) and follicular lymphoma . • Overall response rate ( ORR ) of 75 % and CR rate of 50 % across histologies in CAR T naïve patients , and on par with data from pivotal trials of autologous CAR T therapies .